Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
- Conditions
- Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
- Interventions
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2022-09-07
- Target Recruit Count
- 30
- Registration Number
- NCT05036798
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-09-21
- Target Recruit Count
- 934
- Registration Number
- NCT05035147
- Locations
- 🇨🇳
Rui Liu, Tianjin, Tianjin, China
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
- Conditions
- MSI-H Advanced Colorectal Cancer
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 10
- Registration Number
- NCT05035381
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 30
- Registration Number
- NCT05029973
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Chemotherapy Combined With Apatinib and PD-1 Antibody
- Conditions
- Gastric Cancer
- Interventions
- Drug: PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2023-01-18
- Target Recruit Count
- 30
- Registration Number
- NCT05025033
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine
- Conditions
- Diarrhea Caused by Antitumor Drugs
- Interventions
- Drug: Traditional Chinese Medicine
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2021-08-11
- Target Recruit Count
- 30
- Registration Number
- NCT04988165
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
- Conditions
- PerioperativeSintilimabGastric Cancer
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-08-31
- Target Recruit Count
- 210
- Registration Number
- NCT04982939
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2021-07-21
- Target Recruit Count
- 2000
- Registration Number
- NCT04970264
- Locations
- 🇨🇳
TianJin Medical University Cancer Institute and Hospital, Tianjin, China
Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations
- Conditions
- ImmunotherapyAdjuvant TherapyColon CancerMSI-H
- Interventions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2021-07-20
- Target Recruit Count
- 30
- Registration Number
- NCT04969029
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Breast Mesh Used in Two-staged Breast Reconstruction
- Conditions
- Breast CancerRadiationBreast ReconstructionSynthetic Mesh
- Interventions
- Procedure: TiLoop Bra mesh in expander-implant breast reconstrutionProcedure: sub-pectoral expander-implant breast reconstruction
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2021-07-20
- Target Recruit Count
- 300
- Registration Number
- NCT04967976
- Locations
- 🇨🇳
Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Jilin Cancer Hospital, Ch'ang-ch'un, Jilin, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China